Canada Markets close in 5 hrs 29 mins

Catalyst Biosciences, Inc. (CBIO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.38000.0000 (0.00%)
As of 04:00PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.3800
Open0.4199
Bid0.3800 x 800
Ask0.3999 x 900
Day's Range0.3706 - 0.4199
52 Week Range0.3500 - 5.2000
Volume66,396
Avg. Volume5,018,588
Market Cap11.936M
Beta (5Y Monthly)1.97
PE Ratio (TTM)N/A
EPS (TTM)-3.0550
Earnings DateMar 02, 2022 - Mar 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateAug 20, 2015
1y Target Est11.33
  • GlobeNewswire

    Catalyst Biosciences Sells Complement Portfolio for $60 Million

    SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it has signed a definitive asset purchase and sale agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) under which Vertex has acquired Catalyst’s portfolio of protease medicines that regulate complement, including CB 2782-PEG, for $60 million in cash. Management Comments“We have been exploring strategic alternatives to monetize our assets and maximize value f

  • GlobeNewswire

    Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results

    SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2022. “In the first quarter, we regained the rights to CB 2782-PEG, a C3 degrader protease, for the potential treatment of dry age-related macular degeneration (“AMD”) and now have full rights to two wholly-owned, potential best-in-class complement candidates that may provide compelling opportunities in o

  • Simply Wall St.

    Here's Why Catalyst Biosciences (NASDAQ:CBIO) Must Use Its Cash Wisely

    We can readily understand why investors are attracted to unprofitable companies. For example, although...